Scripius and Avera collaborate to reduce prescription costs

Better oncology drug management could lead to improved outcomes, lower costs

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

July 26, 2024

Vol.50 No.30

By Matt Ingram

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Turning the page: Projections for cancer care in the coming year

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

A confirmation hearing for NCI Director Monica Bertagnolli will take place sometime in October, said Sen. Bernie Sanders (I-VT), chairman of the Senate Health, Education, Labor, and Pensions Committee.

September 15, 2023

Vol.49 No.34

By Matthew Bin Han Ong

White House

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
PhRMA sues to block the program

The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.

September 08, 2023

Vol.49 No.33

By Matthew Bin Han Ong

Scripius and Avera collaborate to reduce prescription costs

YOU MAY BE INTERESTED IN

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Turning the page: Projections for cancer care in the coming year

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
PhRMA sues to block the program

Renew today!

Subscriber content

Never miss an issue!

Login

Scripius and Avera collaborate to reduce prescription costs

YOU MAY BE INTERESTED IN

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Turning the page: Projections for cancer care in the coming year

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Obstacles cleared for Bertagnolli’s confirmation as NIH directorSenate HELP Committee schedules hearing

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part DPhRMA sues to block the program

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
PhRMA sues to block the program